Engrail Therapeutics
PrivateLast Round
Series B
Extension
Aug 8, 2024
Total Funding Raised
$241M
Company Overview
Engrail Therapeutics is a clinical-stage pharmaceutical company that develops precision-targeted therapies for patients with neuropsychiatric and neurodevelopmental disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine, Mental Health
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Engrail Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Engrail Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Aug 8, 2024 | ||||
| Series B | Mar 19, 2024 | ||||
| Series A Extension | Aug 3, 2021 | ||||
| Series A | Jun 18, 2020 |
Key People
Founding team and executive leadership
Engrail Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion | Series B |
| abrdn Inc. | Series B |
| F-Prime Capital | Series B |
| Eight Roads Ventures | Series B |
| Ysios Capital | Series B |
| Nan Fung Life Sciences | Series A Extension, Series A |
| Norwest Venture Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 16, 2025
ENX-101 evaluated for antiseizure effects in GAERS model.
Engrail Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Engrail Therapeutics's valuation, stock price, and market status.